| Initial model | Final model | ||
---|---|---|---|---|
 | OR (95% CIs) | P-value | OR (95% CIs) | P-value |
Male gender | 1.66 (0.88-3.13) | 0.1 | 1.88 (1.03-3.44) | 0.04 |
Age | 1.02 (0.99-1.04) | 0.3 | Â | Â |
DM | 0.92 (0.49-1.76) | 0.8 | Â | Â |
Smoking | 0.62 (0.36-1.07) | 0.09 | 0.57 (0.33-0.96) | 0.04 |
CAD | 1.34 (0.65-2.77) | 0.4 | Â | Â |
PAD | 1.53 (0.65-3.58) | 0.3 | Â | Â |
Cerebrovascular disease | 0.14 (0.02-1.004) | 0.05 | 0.15 (0.02-1.14) | 0.07 |
Baseline LDL-C (mg/dl) | 0.99 (0.98-0.99) | <0.001 | 0.99 (0.98-0.99) | <0.001 |
Combined therapy with statin and ezetimibe | 1.15 (0.56-2.34) | 0.7 | Â | Â |
Very high potency LDL-C lowering regimen | 1.94 (0.84-4.49) | 0.1 | 2.21(1.15-4.24) | 0.02 |